SAN FRANCISCO, Feb. 23, 2011 /PRNewswire/ -- Swift Biosciences Inc., a developer of innovative genetic analysis tools for the diagnostic industry, today presented two applications of their myT™ Primer qPCR. Results were presented for quantitative polymerase chain reaction (qPCR) assays that can detect mutations in two cancer genes: KRAS and BRAF. These assays were evaluated for analytical sensitivity and specificity in model and clinical research samples. In both cases myT Primer assays demonstrated very high sensitivity: each was capable of detecting a single copy of the corresponding mutant template molecule with virtually no background. When compared to a leading commercially available KRAS qPCR mutation test kit, myT Primer assays demonstrated on average several orders of improved specificity. myT Primer assays were also effective with clinical research samples; single copy sensitivity was achieved for KRAS assays when used to genotype formalin fixed paraffin embedded (FFPE) specimens from Stage III colorectal tumors. Similar results were obtained for BRAF assays when used to genotype melanoma FFPE specimens.
Swift Biosciences also reported proof of concept with myT Primers for the detection of mutations found in both circulating tumor cells and cell-free serum or plasma DNA. Limiting dilutions of cultured cancer cells harboring KRAS mutations were added to whole human blood and subjected to allele-specific myT Primer assays; single copy detection of mutant alleles was observed in a background of 14,000 copies (50 ng) of wild type genomic DNA. Plasmid mixing experiments suggest that the absolute limit for myT Primer analytical selectivity may be as low as 1 in 100 million.
"We are excited about the exceptional performance of the myT Primer qPCR assays on clinical research samples," said Valdimir Makarov, PhD and Chief Scientific Officer at Swift Biosciences. Dr. Makarov added, "We feel that myT Primers a
|SOURCE Swift Biosciences Inc.|
Copyright©2010 PR Newswire.
All rights reserved